FFL
CRSP icon

Financial Freedom LLC’s CRISPR Therapeutics CRSP Stock Holding History

Financial Freedom LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$4.76K – 164
2026
Q1 		$4.76K Hold
100
– – ﹤0.01% 362
2025
Q4 		$5.24K Hold
100
– – ﹤0.01% 295
2025
Q3 		$6.48K Hold
100
– – ﹤0.01% 300
2025
Q2 		$4.86K Hold
100
– – ﹤0.01% 309
2025
Q1 		$3.4K Hold
100
– – ﹤0.01% 325
2024
Q4 		$3.94K Hold
100
– – ﹤0.01% 320
2024
Q3 		$4.7K Hold
100
– – ﹤0.01% 311
2024
Q2 		$5.4K Hold
100
– – ﹤0.01% 315
2024
Q1 		$6.82K Hold
100
– – ﹤0.01% 298
2023
Q4 		$6.26K Hold
100
– – ﹤0.01% 302
2023
Q3 		$4.54K Buy
+100
New +$5.17K ﹤0.01% 317

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Financial Freedom LLC's CRSP Position: Q2 2026 in Review

Financial Freedom LLC sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 100 shares — an estimated $4.76K sold.

Financial Freedom LLC first reported a position in CRSP in Q3 2023 and held it in 11 quarters. The position peaked at $6.82K in Q1 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Financial Freedom LLC reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Financial Freedom LLC sold 100 CRISPR Therapeutics shares in Q2 2026, an estimated $4.76K.
  • Financial Freedom LLC first reported a position in CRISPR Therapeutics in Q3 2023 and held it in 11 quarters.
  • Financial Freedom LLC's CRISPR Therapeutics position peaked at $6.82K in Q1 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Financial Freedom LLC's 13F filing for Q2 2026, filed 6 Aug 2026.